Literature DB >> 19814677

Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.

Anita Kolnagou1, Dilek Yazman, Charalambos Economides, Eleni Eracleous, George J Kontoghiorghes.   

Abstract

Excess cardiac iron deposition leads to congestive cardiac failure and accounts for more than 70% of deaths in thalassemia major patients. In three separate studies involving 145 thalassemia patients, serum ferritin and magnetic resonance imaging (MRI) relaxation times T2 and T2* have been compared for assessing iron load levels during chelation treatment. In two studies, variable levels of cardiac iron load have been detected by T2 and T2* in patients treated with deferoxamine (DFO), which, however, were unrelated to serum ferritin. In most cases, similar range levels from normal to severe cardiac iron load could be identified by both the T2 and T2* methods. However, in a few cases there were substantial differences in the levels detected between the two methods. In the third study, the ferrikinetics of the normalization of the iron stores during the International Committee on Chelation (ICOC) deferiprone (L1)/DFO combination protocol was followed up using T2 and T2* and serum ferritin. Iron deposits were found not to be proportionally distributed between the liver and the heart or uniformly distributed within each organ. Iron mobilization in each patient varied and iron deposits in each organ were cleared at different rates. Despite some limitations, the application of the MRI relaxation times T2 and T2* offers the best diagnostic methods for iron overload estimations in most organs and especially the heart. These MRI methods and serum ferritin could also be used for the ferrikinetics of iron mobilization and removal during chelation therapy and the normalization of the iron stores during the ICOC L1/DFO combination protocol. There is a need to standardize the two MRI relaxation times T2 and T2* methods and identify the factors causing the differences between them.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19814677     DOI: 10.3109/03630260903213231

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  9 in total

1.  Future challenges in the use of magnetic resonance imaging for the diagnosis of iron overload.

Authors:  Annita Kolnagou; George J Kontoghiorghes
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

2.  Comparison of myocardial T1 and T2 values in 3 T with T2* in 1.5 T in patients with iron overload and controls.

Authors:  Gabriel C Camargo; Tamara Rothstein; Flavia P Junqueira; Elsa Fernandes; Andreas Greiser; Ralph Strecker; Viviani Pessoa; Ronaldo S L Lima; Ilan Gottlieb
Journal:  Int J Hematol       Date:  2016-02-12       Impact factor: 2.490

3.  Evaluation of liver tissue by ultrasound elastography and clinical parameters in children with multiple blood cell transfusions.

Authors:  Georg W Wurschi; Karim Kentouche; Karl-Heinz Herrmann; Ines Krumbein; Mariana Nold; James F Beck; Jürgen R Reichenbach; Hans-Joachim Mentzel
Journal:  Pediatr Radiol       Date:  2019-03-29

4.  Evaluation of Iron Overload in the Heart and Liver Tissue by Magnetic Resonance Imaging and its Relation to Serum Ferritin and Hepcidin Concentrations in Patients with Thalassemia Syndromes.

Authors:  Volkan Karakus; Ayşegül Kurtoğlu; Dilek Ersil Soysal; Yelda Dere; Selen Bozkurt; Erdal Kurtoğlu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-07       Impact factor: 0.900

5.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 6.  Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.

Authors:  Annita Kolnagou; Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-12-26

Review 7.  Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.

Authors:  George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

Review 8.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

Review 9.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.